TABLE 2.
Percentages of individuals with antisqualene IgG and IgM antibodies after vaccination with influenza vaccine with or without the MF59 adjuvant
| Antibody | Time point | No. of subjects positive/total no. of subjects (%)
|
P value
|
||
|---|---|---|---|---|---|
| Vaccine with MF59 adjuvant | Vaccine without adjuvant | χ2 test | Logistic regressiona | ||
| IgG | Prevaccination | 48/48 (100) | 52/52 (100) | 1.000 | 0.236* |
| 1 mo postvaccination | 47/48 (97.9) | 51/52 (98.1) | 0.954 | 0.901† | |
| 6 mo postvaccination | 48/48 (100) | 49/52 (94.2) | 0.091 | ||
| IgM | Prevaccination | 28/48 (58.3) | 27/52 (51.9) | 0.520 | 0.446* |
| 1 mo postvaccination | 26/48 (54.2) | 30/52 (57.7) | 0.722 | 0.910† | |
| 6 mo postvaccination | 28/48 (58.3) | 25/52 (48.1) | 0.305 | ||
a
P values in the last column were generated by bivariate logistic regression with vaccine type (*) and time (†) as cofactors.